minoxidil
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
2086
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
September 28, 2026
Pediatric alopecia universalis with poliosis post-psychosocial stress: a case report on methotrexate and adjunctive management.
(PubMed, Acta Dermatovenerol Alp Pannonica Adriat)
- "Initial treatment included topical clobetasol propionate 0.05% for 6 months, topical minoxidil 5% for 12 months, and oral vitamin D supplementation for 6 months, with minimal response. This case highlights psychosocial stress as a potential contributor in pediatric AU and supports a multidisciplinary approach. Methotrexate was effective and well tolerated, and poliosis may be a marker of follicular recovery."
Journal • Alopecia • Immunology • Pediatrics
September 27, 2026
Efficacy and Safety of Platelet-Rich Plasma Versus Topical Minoxidil in Androgenetic Alopecia: A Systematic Review.
(PubMed, Cureus)
- "Single-agent regimens provide partial responses without clear overall dominance. Adding monthly PRP injections to daily 5% minoxidil demonstrates promising comparative efficacy for vertex density restoration, though further standardized trials are warranted."
Journal • Review • Alopecia • Immunology
September 27, 2026
Radiofrequency Microporation Enhances Topical Minoxidil Delivery and Hair Regeneration in Androgenetic Alopecia.
(PubMed, Pharmaceutics)
- " RF microporation creates transient microchannels that enhance cutaneous MNX delivery and improve hair-regrowth efficacy. Importantly, RF-assisted topical administration maintained substantially lower systemic exposure than oral administration, supporting its potential as a needle-free strategy for topical AGA therapy and further translational evaluation."
Journal • Alopecia • Immunology
September 25, 2026
Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics.
(PubMed, PLoS One)
- "This study systematically evaluated associations between AGA drugs and male infertility using real-world pharmacovigilance data and integrated bioinformatic analyses. The HIF1A-related transcriptomic findings provide a hypothesis-generating biological context for male infertility but do not establish a shared or drug-specific mechanism linking the three medications to infertility. The pharmacovigilance findings indicate reporting signals rather than incidence or causality."
Adverse events • Journal • Alopecia • Immunology • Infertility • Sexual Disorders • FGF • HIF1A
September 11, 2026
Dupilumab Combined with Topical 5% Minoxidil for Severe Alopecia Areata in a 2-Year-Old Child with Type 2 Immune Features: A Case Report.
(PubMed, Clin Cosmet Investig Dermatol)
- "This case adds to emerging evidence that dupilumab may be considered in carefully selected pediatric patients with severe, treatment-refractory AA and features suggestive of type 2 immune involvement. Because minoxidil was continued concomitantly, baseline inflammatory activity was limited, and spontaneous regrowth cannot be excluded, the clinical improvement cannot be attributed to dupilumab alone."
Journal • Alopecia • Dermatology • Immunology • Inflammation • Pediatrics
September 03, 2026
Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.
(PubMed, JAMA Dermatol)
- "Oral Janus kinase inhibitors represented the primary, long-term therapy for all patients, with dupilumab as an alternative option for patients with comorbid atopy. Supplemental treatments included oral and topical minoxidil; intralesional, oral, and high-potency topical corticosteroids; and topical Janus kinase inhibitors and prostaglandins, with body site-specific indications...Additional high-quality investigations are needed to establish the efficacy of existing therapies in subpopulations and enable head-to-head comparisons of new and existing interventions. These recommendations are not indicated for children, pregnant patients, patients with mild to moderate disease, or those with underlying comorbidities; additional research is needed to inform treatment guidelines for these specific patient populations."
Clinical • Journal • Alopecia • Immunology • Pediatrics
June 29, 2026
Oral medications for hair loss in the elderly
(EADV 2026)
- "This includes low-dose oral minoxidil, finasteride, dutasteride, spironolactone, hydroxychloroquine and JAK inhibitors. Learning Objectives After this presentation, participants should be able to: Select suitable oral treatments for androgenetic alopecia, frontal fibrosing alopecia and alopecia areata.Assess cardiovascular, renal, thrombotic, infectious and oncological risks before treatment. Apply recent recommendations on low-dose oral minoxidil and JAK inhibitors."
Clinical • Alopecia • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Lichen Planus • Nephrology • Renal Disease • Thrombosis
September 23, 2026
Improved transcutaneous delivery of cetirizine hydrochloride for the treatment of post-chemotherapy alopecia: Poke and emulgel approach.
(PubMed, Pak J Pharm Sci)
- "The prepared cetirizine HCl-loaded emulgel and microneedle combination may be a promising approach to treating chemotherapy-induced alopecia."
Journal • Alopecia • Cardiovascular • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Oncology
September 23, 2026
ROS-Scavenging Hyperbranched Polymer Dot Nanozymes Combined with Fractional CO2 Laser Microchannels for Hair Follicle Regeneration.
(PubMed, Int J Nanomedicine)
- "Laser microchannels act as both delivery portals and regenerative triggers, while HPD scavenges post-injury reactive oxygen species and sustains Wnt/β-catenin activation, producing a greater-than-additive acceleration of hair follicle regeneration exceeding minoxidil. This reflects activation and accelerated growth of existing follicles rather than de novo neogenesis, and offers a drug-free platform for regenerative dermatology."
Journal • Aesthetic Medicine • Dermatology
September 22, 2026
Hair and Scalp Effects of GLP-1 Receptor Agonists in Practice.
(PubMed, Clin Dermatol)
- "Management strategies include nutritional optimization with protein targets of 1.2-2.0 g/kg/day based on adjusted body weight, patient counseling on the anticipated time course of hair shedding, and pharmacologic options including low-dose oral minoxidil. The hair loss profile of GLP-1 RAs is compared with that of bariatric surgery, where pooled incidence ranges from 47%-57%. Practical guidance for the clinician is provided throughout."
Journal • Alopecia • Immunology
August 06, 2026
Oral minoxidil enhances early response to baricitinib in moderate-to-severe alopecia areata. A retrospective study of 59 patients.
(EADV 2026)
- No abstract available
Retrospective data • Alopecia • Immunology
August 06, 2026
Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial
(EADV 2026)
- No abstract available
Clinical
August 06, 2026
Early Intervention of 5% Minoxidil Usage Yields Improved Hair Regrowth in Male Androgenetic Alopecia: The Effects of Age and Stage
(EADV 2026)
- No abstract available
Alopecia • Immunology
August 06, 2026
Safety of low dose oral minoxidil in healthy South Asian adult population
(EADV 2026)
- No abstract available
Clinical
August 06, 2026
Adjunctive Non-Ablative Fractional 1550-nm Diode Laser With 2% Topical Minoxidil for Female Pattern Hair Loss: A Split-Scalp Case Series in Asian Women With Fitzpatrick Skin Types IV–V
(EADV 2026)
- No abstract available
Clinical • Alopecia
August 06, 2026
Cardiovascular Safety and Efficacy of Low-Dose Oral Minoxidil 5 mg Daily in Men with Androgenetic Alopecia: An Open-Label, Prospective Pilot Study with Echocardiographic Evaluation (MAACD Study)
(EADV 2026)
- No abstract available
Clinical • Alopecia • Cardiovascular • Immunology
August 06, 2026
Hair regrowth in female androgenetic alopecia combining microneedling-assisted delivery of minoxidil and dutasteride with topical minoxidil and oral spironolactone
(EADV 2026)
- No abstract available
Alopecia • Immunology
August 06, 2026
Comparison of effectiveness and safety of low-dose oral minoxidil (1.25 mg) versus topical 5% minoxidil in male androgenetic alopecia: a randomized open-label pilot study
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology
August 06, 2026
Crowning Glory: Safety and efficacy of 1.25 mg versus 2.5 mg oral minoxidil in male androgenic alopecia
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology
August 06, 2026
Comparison Of Efficacy Between 5% Minoxidil And 5% Procapil In Patients With Androgenetic Alopecia
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology
August 06, 2026
Cardiovascular Safety of Oral Minoxidil Use in Dermatologic Patients: A Systematic Review and Meta-Analysis
(EADV 2026)
- No abstract available
Retrospective data • Review • Cardiovascular
August 06, 2026
Efficacy and Safety of Low-Dose Oral versus Topical Minoxidil in Androgenetic Alopecia: A Double-Blind, Double-Dummy Randomized Controlled Trial in a South Asian Population
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology
August 06, 2026
Evaluation of the Efficacy of Exosome versus Platelet-Rich Plasma or Minoxidil in Treatment of Androgenetic Alopecia
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology
August 06, 2026
Raynaud's phenomenon associated with concomitant use of topical minoxidil
(EADV 2026)
- No abstract available
Cardiovascular • Rheumatology
August 06, 2026
Evaluation of the Sulfotransferase activity in Androgenetic alopecia patients using genotyping of SULT1A1 to predict the individual's response to oral minoxidil.
(EADV 2026)
- No abstract available
Clinical • Alopecia • Immunology • SULT1A1
1 to 25
Of
2086
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84